View Older Stories View More Recent Stories

Sep 5, 2017 07:00AM Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA Meeting

Aug 10, 2017 11:30AM Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) to Ring The Nasdaq Stock Market Opening Bell

Aug 8, 2017 11:25AM Citius Pharmaceuticals, Inc. Announces Closing of Public Offering

Aug 3, 2017 09:36AM Citius Pharmaceuticals (CTXR) Prices $6.8M Public Offering of Common Stock, Warrants

Aug 3, 2017 09:31AM Citius Pharmaceuticals, Inc. Prices $6,800,000 Public Offering And Listing On The Nasdaq Capital Market

Jun 13, 2017 10:37AM Citius Pharmaceuticals Presents At The 2017 Marcum MicroCap Conference

Jun 8, 2017 05:00PM Citius Pharmaceuticals Announces Reverse Stock Split

Jun 6, 2017 12:30PM Citius Pharmaceuticals to Present at the 7th Annual LD Micro Invitational

Mar 23, 2017 07:00AM Citius Pharma Announces Addition of South America to World License

Feb 10, 2017 07:00AM Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

Jan 11, 2017 07:00AM Citius' Mino-Lok™ Addresses Resistant Pathogens

Dec 21, 2016 07:00AM Citius Pharmaceuticals to Present at 9th Annual Biotech Showcase

Dec 8, 2016 07:00AM Citius Moves Forward with Mino-Lok™ Phase 3 Trial

Oct 20, 2016 07:00AM Citius Pharmaceuticals to Present at the Dawson James 2016 Small Cap Growth Stock Conference

Sep 19, 2016 07:00AM Citius Pharmaceuticals to Present at the 2016 Aegis Growth Conference

Sep 13, 2016 07:00AM Citius Initiates Mino-Lok™ Phase 3 Trial

Sep 8, 2016 07:00AM Citius Pharmaceuticals, Inc., Initiates Manufacturing of Mino-Lok™

Sep 8, 2016 07:00AM Citius Pharmaceuticals, Inc., Initiates Manufacturing of Mino-Lok™

Sep 7, 2016 10:32AM Citius Pharmaceuticals to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Sep 7, 2016 10:32AM Citius Pharmaceuticals to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Aug 23, 2016 07:00AM Citius Announces Completion of In-Depth Interviews on Patient-Reported Outcomes: Signs and Symptoms of Hemorrhoids and Treatments

Aug 1, 2016 07:00AM Citius Pharmaceuticals Provides Shareholder Update on Recent Achievements

Jul 25, 2016 07:00AM Citius Pharmaceuticals Addresses Problem That Affects 10 Million People in the U.S.: Hemorrhoids

Jul 18, 2016 07:00AM Citius Pharmaceuticals Completes Feasibility Study of Investigator Sites for Mino-Lok™ Phase 3 Trials

Jul 1, 2016 05:00PM Citius Pharmaceuticals Discontinues Suprenza™ To Focus on Core Assets

Jun 28, 2016 07:00AM Citius Pharmaceuticals, Inc. Announces Appointment of Dr. Eugene Holuka to Its Board of Directors

May 12, 2016 07:00AM Citius Announces Completion of Private Placement Financing

Apr 4, 2016 07:00AM Citius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences

Mar 23, 2016 07:00AM Citius Pharmaceuticals Announces Significant Equity Investment from Chairman and CEO

Mar 7, 2016 07:00AM Citius Pharmaceuticals Signs Letter of Intent to Acquire Leonard Meron Biosciences

Feb 1, 2016 07:00AM Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids

Oct 8, 2015 07:00AM Citius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors

Oct 6, 2015 07:00AM Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors

View More Recent Stories View Older Stories